- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We're Reading: J&J to Show Drug Prices; SCOTUS Blocks Abortion Law; Democrats' Medicare Bill
Johnson & Johnson will become the first drug maker to begin showing the list price of its prescription drugs in television ads; in a 5-4 decision, the Supreme Court blocked a Louisiana law that required doctors performing abortions to have admitting privileges at nearby hospitals; Democrats unveiled a bill to allow Medicare to negotiate drug prices.
J&J to Start Listing Drug Prices in TV Ads, Starting With Xarelto
Johnson & Johnson will become the first drug maker to begin showing the list price of its prescription drugs in television ads, the Associated Press reported. The first drug it will start with is its blood thinner Xarelto. By late March, commercials will give the pill’s list price plus typical out-of-pocket costs.
High Court Blocks Louisiana Abortion Law
In a 5-4 decision, the Supreme Court blocked a Louisiana law that required doctors performing abortions to have admitting privileges at nearby hospitals, The New York Times reported. Opponents of the law said it could have left the state with just 1 doctor authorized to provide abortions. Chief Justice John G. Roberts Jr joined the court’s 4-member liberal wing.
Democrats Unveil Bill Requiring Medicare to Negotiate Drug Prices
Led by Senator Sherrod Brown, D-Ohio, who is considering a presidential run, Democrats unveiled a bill to allow Medicare to negotiate drug prices, a key part of their agenda to lower pharmaceutical costs. Joined by Representative Lloyd Doggett, D-Texas, the chairman of the House Ways and Means Health Subcommittee, Brown said he hoped that President Trump would listen to “candidate Trump,” referring to when Trump said during his campaign that he supported the idea, before reversing his position. The bill has long odds of passage, The Hill noted.
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
The Impact of Cost Sharing on High-Value Care
March 14th 2025Michael Chernew, PhD, professor of health care policy and director of the Healthcare Markets and Regulation Lab, Harvard Medical School, shares how cost-sharing policies shape access to critical health care services and influence value-based insurance design.
Read More
